Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease

2015 ◽  
Vol 15 (5) ◽  
pp. 307-312 ◽  
Author(s):  
Sabrina Rossi ◽  
Michele Basso ◽  
Antonia Strippoli ◽  
Vincenzo Dadduzio ◽  
Eleonora Cerchiaro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Her2 Expression ◽  
Axillary Metastases ◽  
Receptor Status

Hormone receptor status in primary breast cancer—time for a consensus?

2002 ◽  
Vol 38 (9) ◽  
pp. 1201-1203 ◽  
Author(s):  
G.C Wishart ◽  
M Gaston ◽  
A.A Poultsidis ◽  
A.D Purushotham
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Receptor Status

scholarly journals Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?

2019 ◽  
Vol 18 (2) ◽  
pp. 78-82
Author(s):  
O. O. Gordeeva ◽  
L. G. Zhukova ◽  
I. V. Kolyadina ◽  
I. P. Ganshina
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Hormone Receptor Status ◽  
Primary Tumors ◽  
Receptor Status ◽  
Regional Metastases

Background. Assessment of hormone receptor status plays a crucial role in treatment of patients with breast cancer. currently, clinicians are limited to determining the expression status of estrogen receptor (ER), progesterone receptor (pR) and HER2 only in primary breast cancer tissues, even in the presence of regional metastases.The purpose of the study was to review available data on heterogeneity of ER, pR and HER2/neu expressions in primary breast cancer and regional metastases.Material and methods. We analyzed publications available from pubmed, medline etc. using the keywords «discordance», «breast cancer», «locally advanced», «regional lymph nodes», «ER», «pR», and «HER2».Results. The clinical and prognostic role in assessing the heterogeneity of the receptor status of primary tumors and synchronous regional metastases, as well as the effect of detected discordance on treatment tactics was assessed.Conclusion. Data on the frequency of discordance in hormone receptor status between primary and metastatic breast cancer tumors and its effect on the further prognosis in breast cancer are still contradictory. However, the fact of the presence of such heterogeneity suggests that some patients with affected lymph nodes will have significant benefits from determining the status of steroid hormones and HER2 not only in the primary tumor, but also in the lymph nodes, since it will open up new opportunities for subsequent targeted therapy.

Comparative study of hormone receptor status and HER2 expression between primary and recurrent breast cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e21050-e21050
Author(s):  
N. Rokutanda ◽  
J. Horiguchi ◽  
D. Takata ◽  
R. Nagaoka ◽  
A. Sato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Comparative Study ◽  
Hormone Receptor ◽  
Recurrent Breast Cancer ◽  
Hormone Receptor Status ◽  
Her2 Expression ◽  
Receptor Status ◽  
Recurrent Breast

scholarly journals Second Primary Breast Cancer Occurrence According to Hormone Receptor Status

2009 ◽  
Vol 101 (15) ◽  
pp. 1058-1065 ◽  
Author(s):  
A. W. Kurian ◽  
L. A. McClure ◽  
E. M. John ◽  
P. L. Horn-Ross ◽  
J. M. Ford ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Second Primary ◽  
Receptor Status ◽  
Cancer Occurrence

scholarly journals Risk of contralateral second primary breast cancer according to hormone receptor status in Germany

2014 ◽  
Vol 16 (5) ◽  
Author(s):  
Carsten Rusner ◽  
Katharina Wolf ◽  
Ulrike Bandemer-Greulich ◽  
Jutta Engel ◽  
Christa Stegmaier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Second Primary ◽  
Receptor Status
Sign in / Sign up

Export Citation Format

Share Document